엔비디아는 행정적 부담을 줄여 임상 시험 속도를 높이는 AI 에이전트를 비롯해 생물학적 기기에서 학습해 신약 개발과 디지털 병리학을 발전시키는 AI 모델, 수술·환자 모니터링·운영을 위한 물리 AI 로봇 등에 솔루션을 지원한다.
AI computing support including IQVIA, Illumina, and Mayo
NVIDIA supports solutions such as AI agents that accelerate clinical trials by reducing administrative burdens, AI models that learn from biological devices to advance new drug development and digital pathology, and physical AI robots for surgery, patient monitoring, and operations.
On the 15th, NVIDIA announced a $10 trillion innovation partnership in the healthcare and life sciences industry at the JP Morgan Healthcare Conference held in San Francisco, USA on the 13th.
It was reported that through this partnership, they will accelerate new drug development, strengthen genome research, and pioneer cutting-edge medical services utilizing agentic AI and generative AI.
Healthcare industry innovation companies IQVIA, Illumina, Mayo Clinic, and Arc Institute are using the latest NVIDIA technology to develop solutions that help improve human health.
“AI can advance medicine and life sciences with tools that help clinicians detect diseases earlier and discover new treatments faster,” said Kimberly Powell, vice president of healthcare at NVIDIA. “NVIDIA’s AI and accelerated computing capabilities, combined with the expertise of industry leaders, will enable healthcare and life sciences to advance medicine and life sciences.” “Biological innovation will be unlocked,” he said.
■ IQVIA, AI Foundry Utilization Development IQVIA is building custom foundation models based on over 64 petabytes (PB) of data through NVIDIA AI Foundry services and is also developing agentic AI solutions with NVIDIA AI Enterprise software.
“This is a quantum leap forward in how AI is applied in healthcare and life sciences,” said Bhavik Patel, president of commercial solutions at IQVIA. “Combined with NVIDIA’s advanced AI technologies, we have built a new solution powered by AI agents trained on world-class medical information and optimized for life science workflows.”
■ Illumina, AI-based new drug development Illumina, a DNA sequencing and informatics company, is working with NVIDIA to make drug discovery and next-generation genomics possible. Through the partnership, Illumina is applying NVIDIA’s accelerated computing and AI toolsets to its multiomics analysis software and workflows.
Illumina announced plans to offer DRAGEN analytics software based on NVIDIA accelerated computing within the Illumina Connected Analytics platform. In addition to developing new biology-based models, NVIDIA and Illumina plan to collaborate to advance multi-omics data analytics on the Illumina Connected Analytics platform.
“Our ability to combine the power of AI with multi-omics data is transforming the way we understand disease,” said Steve Barnard, Illumina’s chief technology officer. “Our goal is to combine genomics data and analytics expertise with our AI platform to enable pharmaceutical and biotech companies to discover insights based on their multi-omics data and improve the success of their therapeutic development.”
■ Mayo, AI-based digital pathology Pathology is an essential tool that clinicians use to diagnose and determine treatment for many types of cancer and other serious and complex health conditions, but it is a slow and manual process.
The Mayo Clinic Digital Pathology Platform is built on an autonomous robotics lab and advanced imaging technology, enabling the creation of foundation models from a dataset of 10 million patient records and 20 million slide images.
NVIDIA and Mayo Clinic plan to deploy NVIDIA DGX Blackwell systems and NVIDIA’s Monai medical imaging platform to accelerate the development of next-generation pathology foundation models. They are also expected to expand their collaboration in the areas of new drug discovery and personalized treatment.
■ Arc Labs Expands Biological AI Models Ark Labs is a research institute based in Palo Alto, California, working at the intersection of biology and machine learning. They are working with NVIDIA to develop and share AI models and tools that accelerate discovery in biomedical science.
Ark Labs biology and machine learning researchers are working with NVIDIA engineers to expand the potential of foundation biology models to generalize across multiple modalities, including DNA, RNA, and proteins, while advancing applications for drug discovery, synthetic biology across multiple levels of complexity, and the study of disease and evolution.
As part of this collaboration, NVIDIA provided Arc Labs with its expertise in large-scale model development, along with the NVIDIA BioNemo platform, NVIDIA NIM microservices, and blueprints running on NVIDIA DGX Cloud.